Daily non-political popular news in brief.

Discovery of new cause of mental retardation simplifies search for treatments

01-24-2008 · EurekAlert!

Two to three children in 100 are born with a mental handicap. This can be caused by a genetic defect, but in 80 percent of the cases scientists do not know which genes are responsible. Now, VIB researchers have discovered that, in a portion of these patients, the mental retardation is caused by a two-fold production of two proteins.

Keywords: discovery, cause, mental, retardation, simplifies, search, treatments, simplify, treatment

« Previous | Next »

Similar news on "Discovery of new cause of mental retardation simplifies search for treatments":

Fragile X retardation syndrome corrected in mice
12-19-2007 · EurekAlert!
Researchers working with mice have significantly alleviated a wide range of abnormalities due to fragile X syndrome by altering only a single gene, countering the effects of the fragile X mutation. They said their achievement offers the potential for treatment of the disorder, the most common form of inherited mental retardation and a leading identified genetic cause of autism. There is currently no treatment or therapy for fragile X syndrome, whose symptoms include mental retardation, epilepsy and abnormal body growth.
Similar news · Read more »
Advance in understanding of blood pressure gene could lead to new treatments
02-04-2007 · EurekAlert!
Research by scientists at UCL (University College London) has clearly demonstrated for the first time the structure and function of a gene crucial to the regulation of blood pressure. The discovery could be important in the search for new treatments for illnesses such as heart disease, the UK's biggest killer. In a paper published online today in Nature Medicine, the team, led by Professor Patrick Vallance and Dr James Leiper, UCL Department of Medicine, reveal the role of the human gene dimethylarginine dimethylaminohydrolase (DDAH), showing that loss of DDAH activity disrupts nitric oxide (NO) production. NO is critical in the regulation of blood pressure, nervous system functions and the immune system. The role of DDAH is to break down modified amino acids (Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA)) that are produced by the body and have been shown to inhibit NO synthase. These molecules accumulate in various disease states including diabetes, renal failure and pulmonary and systemic hypertension, and their concentration in plasma (the fluid component of blood) is strongly predicative of cardiovascular disease and death. In a healthy human body, the majority of ADMA is eliminated through active metabolism by DDAH. Scientists have hypothesised that if DDAH function is impaired, NO production is reduced, and that this could be an important feature of increased cardiovascular risk. To examine this pathway in more detail, the researchers deleted the DDAH gene in mice. These mice went on to develop hypertension, or high blood pressure. They also designed specific inhibitors (small molecules) which bind to the active site of human DDAH. These small molecule inhibitors also induced hypertension in mice, confirming the importance of DDAH in the regulation of blood pressure. Dr Leiper, UCL Medicine, said: “These genetic and chemical approaches to disrupt DDAH showed remarkably consistent results, and provide compelling evidence that loss of DDAH function increases the concentration of ADMA and thereby disrupts vascular NO signalling. “There has been considerable scientific interest in this pathway and the role of ADMA as a novel risk factor, but so far there's been little evidence to support the idea that it's a cause of disease, rather than just a marker. Genes and their pathways are crucial to our understanding of cardiovascular disease and a better understanding of DDAH-1 could lead to important new treatments. “It could help us to establish if genetic variation predisposes certain people to these diseases, or whether environmental factors exert some of their effects through modulation of DDAH activity. “Our research also shows that this pathway could be harnessed therapeutically to limit production of NO in certain situations where too much nitric oxide is a bad thing; for example, hypotension and septic shock. These are some of the biggest problems in intensive care medicine and there is a huge unmet need for drug treatments.” The study, which was carried out at UCL's Rayne Institute, was funded by grants from the British Heart Foundation, the Wellcome Trust and the Medical Research Council. Professor Jeremy Pearson, Associate Medical Director of the British Heart Foundation, said: "The unexpected finding in the 1980s that a simple gas, nitric oxide (NO), is made by cells in the blood vessel wall and is a powerful control of blood vessel relaxation led to the award of the Nobel Prize in 1998 to its discoverers. "More recently, there has been increasing evidence that impairment of NO production is likely to be an important factor in the development of heart and circulatory disease, but the mechanisms responsible are not fully understood. "This study suggests for the first time that the loss of the activity of the enzyme DDAH-1 leads to reduced NO production and may cause heart and circulatory disease. These findings are likely to be important in the search for new ways to optimise the health of our blood vessels." ### Notes for Editors 1. For more information, please contact Ruth Metcalfe in the UCL Media Relations Office on tel: +44 (0)20 7679 9739, mobile: +44 (0)7990 675 947, out of hours: +44 (0)7917 271 364, e-mail: r.metcalfe@ucl.ac.uk2. 'Disruption of methylarginine metabolism impairs vascular homeostasis' is published in the February issue of the journal Nature Medicine. Advance online publication is embargoed to 18.00 GMT (13.00 US Eastern) Sunday 4 February 2007. Journalists can obtain copies of the paper by contacting the UCL Media Relations Office.3. The study was funded by the British Heart Foundation, the Wellcome Trust and the Medical Research Council. About UCL Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the government's most recent Research Assessment Exercise, 59 UCL departments achieved top ratings of 5* and 5, indicating research quality of international excellence. UCL is the fourth-ranked UK university in the 2006 league table of the top 500 world universities produced by the Shanghai Jiao Tong University. UCL alumni include Mahatma Gandhi (Laws 1889, Indian political and spiritual leader); Jonathan Dimbleby (Philosophy 1969, writer and television presenter); Junichiro Koizumi (Economics 1969, Prime Minister of Japan); Lord Woolf (Laws 1954, Lord Chief Justice of England & Wales); Alexander Graham Bell (Phonetics 1860s, inventor of the telephone), and members of the band Coldplay.
Similar news · Read more »
How Rett Syndrome mutation targets the brain
10-18-2006 · EurekAlert!
Researchers have pinpointed why mutations that cause Rett Syndrome (RTT) -- among the leading causes of mental retardation in females -- specifically target the brain rather than other body tissues. They said their findings yield important insight into the origin and course of the disease.
Similar news · Read more »
Common cancer treatments toxic to healthy brain cells
11-29-2006 · EurekAlert!
Common drugs used to treat cancer may be more harmful to healthy brain cells than the cancer cells that they are intended to destroy, according to a new study. The results, which also indicate that chemotherapy may cause long-term brain damage, represent the closest that scientists have come to pinpointing the underlying physiological cause of "chemo brain," a common side effect of cancer treatment that scientists are only now beginning to comprehend.
Similar news · Read more »
Aspirin discovery may improve cancer treatments
04-04-2007 · EurekAlert!
Scientists have uncovered the molecular pathways involved in the inhibition of protein synthesis in cells by aspirin, a discovery that may have implications for the treatment of cancer.
Similar news · Read more »
Scientists take next step in understanding potential target for Ovarian cancer treatment
07-16-2007 · EurekAlert!
A traffic cop protein in the cell may have an even more important role: transporting a messenger protein that tells components in the nucleus to stop cell growth. Scientists are studying the normal function of a protein called 'km23', the traffic cop protein, because the team previously found altered forms of the protein in 42 percent of tumor tissue samples taken from women with Ovarian cancer. The discovery of this additional role may lead to diagnostic tools and earlier treatments for Ovarian cancer.
Similar news · Read more »
ACMG recognizes progress made in newborn screening
07-12-2007 · EurekAlert!
In support of the latest March of Dimes Newborn Screening Report Card, the American College of Medical Genetics urges every state to require complete testing of all newborns for a "core panel" of genetic and congenital conditions. Currently more than 500,000 babies annually are still not screened for the full panel of debilitating or life-threatening disorders. In many of these diseases, serious complications such as death or mental retardation are avoidable only through newborn screening, with appropriate follow-up and treatment.
Similar news · Read more »
Nationwide Children's Hospital involved in expanded access program for treatment of PKU
11-05-2007 · EurekAlert!
Nationwide Children's Hospital announced today its involvement in an expanded access program for sapropterin dihydrochloride, or sapropterin, an investigational treatment for phenylketonuria, a rare genetic metabolic disorder that, if left unmanaged in infants and children, can result in severe mental retardation. Currently, there are eight patients enrolled in the expanded access program at Nationwide Children's.
Similar news · Read more »
Evidence found for novel brain cell communication
07-16-2007 · EurekAlert!
An article published today, July 16, 2007, in Proceedings of the National Academy of Sciences provides strong evidence for a novel type of communication between nerve cells in the brain. The findings may have relevance for the prevention and treatment of epilepsy, and possibly in the exploration of other aspects of brain functions, from creative thought processes to mental illnesses such as schizophrenia. The discovery suggests the first new model of brain function since the 1940s.
Similar news · Read more »
Proteases cause pain in irritable bowel syndrome
02-15-2007 · EurekAlert!
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder in the developed world. It is characterized by altered bowel function, abdominal discomfort, and pain. However, there are few effective treatments for IBS, in part because the molecular mechanisms underlying the disease symptoms have not been well defined. But now, researchers from the University of Calgary have provided evidence that serine proteases and PAR2 might provide new therapeutic targets for the treatment of IBS.
Similar news · Read more »